Double autologous hematopoietic stem cell transplantation for T cell non-Hodgkin's lymphoma

Objective:To evaluate the clinical efficacy and safety of autologous hematopoietic stem cell transplantation(AHSCT) for the aggressive T cell non-Hodgkin's lymphoma(T-NHL).Method:We reported and analyzed 28 patients with aggressive T-NHL retrospectively.The first conditioning regimen was 19 of IEP and 9 of MiFAP.Twenty-three patients received the second AHSCT in 6-8 weeks after the first AHSCT.The conditioning regimen was 9 of IEP and 14 of MiFAP.Result:All engrafted patients had rapid hematopoietic reconstitution.There was no AHSCT related death.All patients were followed-up to February 1st,2011.The median follow-up duration was 28(2-98) months.Eight patients relapsed and then died in 1-6 months,of which 3 had received single AHSCT(SASHCT),and 5 had received double AHSCT(DASHCT).Among 23 patients who had received DASHCT,the 1 and 3 years overall survival(OS) was 95.7% and 76.1%,while the 1 and 3 years progression free survival(PFS) was 95.7% and 71.5%,respectively.Median DFS time was 60 months for the DAHSCT group and was 18 months for the SAHSCT group.Conclusion:DASHCT in tandem for aggressive T cell lymphoma is probably safe and effective.